Our Investments

Newton Biocapital's mission is to generate substantial financial and societal value by providing innovative, breakthrough, and affordable solutions to patients.


DIM3 (Disease in management at the 3rd dimension) is a digital healthcare company co-founded in 2012, whose mission is to develop an application to monitor and improve enteral and parenteral nutrition. The company addresses a huge medical need in a space where awareness is currently low.

Epics Logo

EPICS THERAPEUTICS is developing first-in-class drugs in oncology based on RNA epigenetics. The company focuses on discovery and development of small molecule inhibitors of RNA-modifying enzymes to treat cancer.

Syngergia Medical

SYNERGIA is developing a next-generation, small-form, MRI-safe, implanted neurostimulation device for drug-resistant epilepsy, with a range of further therapeutic applications.


ChromaCure is seeking to discover and develop first-in-class small molecule therapeutics for unmet needs in oncology. The company will develop inhibitors of a novel target that is a key regulator of tumor initiation and progression.

Logo Acticor

Acticor Biotech is a clinical stage biotechnology company, spin-off of INSERM, dedicated to developing an innovative treatment in the therapy of acute thrombotic diseases, including ischemic stroke and pulmonary embolism. Acticor Biotech is built upon the expertise and the results of researches conducted by, the founders: Dr. Martine Jandrot-Perrus at INSERM Paris and Pr. Philippe Billiald at Paris-Sud University.

Sequana Medical

Sequana Medical is a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders.

Logo E4Th基本ロゴ

EditForce developed a unique DNA/RNA editing technology, based on pentatricopeptide repeat (PPR) protein platform technology. The technology has a distinct feature that enables the editing of not only DNA but also RNA, highlighting its difference compared to other technologies, and is thus expected to be applied to a wide range of fields. The platform technology has also different mechanisms to work and isolated IP from other existing DNA editing technologies.